Gut Microbes May Up PD-1 Inhibitor Response.
Confirming the results of animal studies, new research shows that the composition of patients' microbiome influences their response to checkpoint inhibitors. Patients with melanoma who benefit from PD-1 inhibitors carry a greater variety of species and higher numbers of microbes in theClostridialesgroup. Increased abundance of certain bacteria in this group also correlated with higher numbers of CD8+ T cells in patients' tumors.
D000818:Animals; D060908:CTLA-4 Antigen; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma; D061026:Programmed Cell Death 1 Receptor
D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor